Scarica l'app Stockscreener
8.25
0.60%
-0.05
Dopo l'orario di chiusura:
8.15
-0.10
-1.21%
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Will ARS Pharmaceuticals Inc stock recover after earnings2026 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Update Report: Can ARS Pharmaceuticals Inc sustain earnings growthBond Market & Community Verified Trade Signals - baoquankhu1.vn
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals - National Today
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Can ARS Pharmaceuticals Inc stock outperform in a bear market2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
Institution Moves: What analysts say about ARS Pharmaceuticals Inc stock2026 Major Catalysts & Technical Pattern Recognition Alerts - baoquankhu1.vn
Guidance Update: Is ARS Pharmaceuticals Inc a top pick in the sectorProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates - MSN
[ARS] CUMBERLAND PHARMACEUTICALS INC SEC Filing - Stock Titan
How (SPRY) Movements Inform Risk Allocation Models - Stock Traders Daily
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha
SPRY: Expanding neffy access, advancing urticaria trials, and strong global uptake drive future growth - TradingView
SPRY: Expanding neffy access and advancing urticaria trials drive growth, with strong global uptake - TradingView
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
Leerink raises ARS Pharmaceuticals stock price target on sales expansion - Investing.com Australia
Leerink raises ARS Pharmaceuticals stock price target on sales expansion By Investing.com - Investing.com Canada
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises - Investing.com India
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises By Investing.com - Investing.com South Africa
ARS Pharmaceuticals (SPRY) Q3 Loss Of US$51 Million Tests Bullish Profitability Narrative - Sahm
ARS Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ARS Pharmaceuticals Announces Strong 2025 Financial Results and neffy® Commercial Launch Progress, Highlights Global Approvals and Market Expansion - Minichart
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M - AlphaStreet
ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 2026 - MSN
SPRY: neffy’s needle-free nasal spray is transforming emergency allergy care and driving rapid market growth - TradingView
ARS Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategy for Neffy Commercialization 49 - Minichart
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® Commercialization - Investing News Network
ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ARS Pharmaceuticals, Inc. (SPRY) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
ARS Pharmaceuticals (NASDAQ:SPRY) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q4 Revenue $28.1M - marketscreener.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss - marketscreener.com
ARS Pharmaceuticals Reports 2025 Results and neffy Growth - TipRanks
ARS Pharmaceuticals Inc (NASDAQ: SPRY) announces that the regulatory approval timeline for its nasal spray epinephrine product Neffy in Canada has been clarified. - Bitget
ARS Pharmaceuticals 2025 10-K: $84.3M Revenue, $(1.74) EPS - TradingView
ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales - TradingView
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - ChartMill
Aug Levels: Will ARS Pharmaceuticals Inc. stock recover after earningsEarnings Beat & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exploring ARS Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earni - GuruFocus
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY): Analyst Consensus Sees 214% Upside Potential - DirectorsTalk Interviews
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock - Investing.com
SPRY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SPRY PE Ratio & Valuation, Is SPRY Overvalued - Intellectia AI
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Zacks Research - MarketBeat
Can Growing Patient And Provider Adoption Of Neffy Propel ARS Pharma's Stock Upward? - Nasdaq
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring A 213% Potential Upside - DirectorsTalk Interviews
ARS Pharmaceuticals receives European approval nod for children's nasal spray - Traders Union
Market Fear: Can ARS Pharmaceuticals Inc sustain earnings growth2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Returns Recap: Can ARS Pharmaceuticals Inc sustain earnings growthWeekly Stock Analysis & Reliable Price Breakout Signals - baoquankhu1.vn
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Investing News Network
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):